Anil Negi
6 Papers
3 Citations
Anil Negi is an academic researcher. The author has contributed to research in topics: Internal medicine & Latanoprost. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial
David F. Garway-Heath,David P. Crabb,Catey Bunce,Gerassimos Lascaratos,Francesca Amalfitano,Nitin Anand,Augusto Azuara-Blanco,Rupert R A Bourne,David C Broadway,Ian A. Cunliffe,Jeremy P. Diamond,Scott G Fraser,Tuan A. Ho,Keith R Martin,Andrew McNaught,Anil Negi,Krishna Patel,Richard A. Russell,Richard A. Russell,Ameet Shah,Paul G. D. Spry,Katsuyoshi Suzuki,E.T. White,Richard Wormald,Wen Xing,Thierry Zeyen +25 more
TL;DR: This is the first randomised placebo-controlled trial to show preservation of the visual field with an intraocular-pressure-lowering drug in patients with open-angle glaucoma, and visual field preservation was significantly longer in the latanoprost group than in the placebo group.
594
A common variant near TGFBR3 is associated with primary open angle glaucoma
Zheng Li,R. Rand Allingham,Masakazu Nakano,Liyun Jia,Yuhong Chen,Yoko Ikeda,Baskaran Mani,Li Jia Chen,Changwon Kee,David F. Garway-Heath,Sarangapani Sripriya,Nobuo Fuse,Khaled K. Abu-Amero,Khaled K. Abu-Amero,Chukai Huang,Prasanthi Namburi,Kathryn P. Burdon,Kathryn P. Burdon,Shamira A. Perera,Shamira A. Perera,Puya Gharahkhani,Ying Lin,Morio Ueno,Mineo Ozaki,Takanori Mizoguchi,SR Krishnadas,Essam A. Osman,Mei Chin Lee,Anita S Y Chan,Liza-Sharmini Ahmad Tajudin,Tan Do,Aurelien Goncalves,Pascal Reynier,Hong Zhang,Rupert R A Bourne,David Goh,David C Broadway,Rahat Husain,Anil Negi,Daniel H. Su,Ching-Lin Ho,Augusto Azuara Blanco,Christopher Kai-shun Leung,Tina T. Wong,Tina T. Wong,Azhany Yakub,Yutao Liu,Yutao Liu,Monisha E. Nongpiur,Jong Chul Han,Do Nhu Hon,Balekudaru Shantha,Bowen Zhao,Jinghong Sang,Nihong Zhang,Ryuichi Sato,Kengo Yoshii,Songhomita Panda-Jonas,Allison E. Ashley Koch,Leon W. Herndon,Sayoko E. Moroi,Pratap Challa,Jia Nee Foo,Jin-Xin Bei,Yi Xin Zeng,Cameron P. Simmons,Tran Nguyen Bich Chau,Philomenadin Ferdinamarie Sharmila,Merwyn Chew,Blanche Lim,Pansy O.S. Tam,Elaine Chua,Xiao Yu Ng,Victor H. K. Yong,Yaan Fun Chong,Wee Yang Meah,Saravanan Vijayan,Sohn Seongsoo,Wang Xu,Yik Ying Teo,Yik Ying Teo,Jessica N. Cooke Bailey,Jae H. Kang,Jonathan L. Haines,Ching-Yu Cheng,Seang-Mei Saw,E-Shyong Tai,Julia E. Richards,Robert Ritch,Douglas E. Gaasterland,Louis R. Pasquale,Louis R. Pasquale,Jianjun Liu,Jost B. Jonas,Dan Milea,Dan Milea,Ronnie George,Saleh A. Al-Obeidan,Kazuhiko Mori,Stuart MacGregor,Alex W. Hewitt,Alex W. Hewitt,Christopher A. Girkin,Mingzhi Zhang,Periasamy Sundaresan,Lingam Vijaya,David A. Mackey,David A. Mackey,Tien Yin Wong,Jamie E Craig,Xinghuai Sun,Shigeru Kinoshita,Janey L. Wiggs,Chiea Chuen Khor,Zhenglin Yang,Zhenglin Yang,Chi Pui Pang,Ningli Wang,Michael A. Hauser,Kei Tashiro,Tin Aung,Eranga N. Vithana +121 more
TL;DR: Exome Array analysis on POAG cases and controls confirmed strong evidence of association at CDKN2B-AS1 and observed one SNP showing significant association to POAG, which has previously been shown to be strongly associated with optic disc area and vertical cup-to-disc ratio.
Are Patient Self-Reported Outcome Measures Sensitive Enough to Be Used as End Points in Clinical Trials?: Evidence from the United Kingdom Glaucoma Treatment Study
Lee Jones,David F. Garway-Heath,Augusto Azuara-Blanco,David P. Crabb,Catey Bunce,Gerassimos Lascaratos,Francesca Amalfitano,Nitin Anand,Rupert R A Bourne,David C Broadway,Ian A. Cunliffe,Jeremy P. Diamond,Scott G Fraser,Tuan A. Ho,Keith R Martin,Andrew McNaught,Anil Negi,Krishna Patel,Richard A. Russell,Ameet Shah,Paul G. D. Spry,Katsuyoshi Suzuki,E.T. White,Richard Wormald,Wen Xing,Thierry Zeyen +25 more
TL;DR: The present study tested the hypothesis that responses on patient-reported outcome measures (PROMs; secondary outcome measure) differ between patients receiving a topical prostaglandin analog (latanoprost) or placebo eye drops in UKGTS.
53
Retinal Microvascular Dysfunction Occurs Early and Similarly in Mild Alzheimer’s Disease and Primary-Open Angle Glaucoma Patients
Stephanie Mroczkowska,Hala Shokr,Alexandra Benavente-Perez,Anil Negi,Peter Bentham,Doina Gherghel +5 more
TL;DR: In this paper , the similarities and differences in retinal microvascular function between mild Alzheimer's disease (AD) patients, early-stage primary open angle glaucoma (POAG) patients and healthy controls were assessed.
Latanoprost treatment for open angle glaucoma. The United Kingdom Glaucoma Treatment Study: a multicentre, randomised, placebo-controlled clinical trial
David F. Garway-Heath,David P. Crabb,Catey Bunce,Gerassimos Lascaratos,Francesca Amalfitano,Nitin Anand,Augusto Azuara-Blanco,Rupert R A Bourne,David C Broadway,Ian A. Cunliffe,Jeremy P. Diamond,Scott G Fraser,Ta Ho,Keith R Martin,Andrew McNaught,Anil Negi,Krishna Patel,Richard A. Russell,Ameet Shah,Paul G. D. Spry,K Suzuki,E.T. White,Richard Wormald,W Xing,Thierry Zeyen +24 more
- 04 Apr 2015
TL;DR: This is the first placebo-controlled trial to demonstrate VF preservation with an IOP-lowering agent in OAG and it was found that latanoprost treatment reduces incident visual field deterioration, compared with placebo, by 50% over 2 years.
3